

## ANTIBIOTIC RESISTANCE OF BACTERIA IMPLICATED IN URINARY TRACT INFECTIONS IN DIABETIC WOMEN

Mansour, F. A.\*; Ghali, M. F.\*\*

and El-Kenawy, A. Zeinab

Botany Department Faculty of Science, Mansoura University\*

Botany Department Faculty of Science, Zagazig University\*\*

### ABSTRACT

Urinary tract infections are amongst the most common pathogenic infections with an increasing resistance to antimicrobials. Isolates from urine samples were identified and their susceptibility to antimicrobial agents were studied, also synergistic and antagonism of the combined antibiotics against bacterial isolates and electron microscope study against multi-drug resistant bacteria were studied. During the study, 211 urine samples from diabetic and non diabetic female patient were analysed, of which 115 had significant bacteriuria (98 from diabetic and 17 from non diabetic). For diabetic patient, *Escherichia coli* was the most common etiologic agent 27 (27.6%) followed by *Serratia* 12(12.2%), *Citrobacter*, *Enterobacter* and *Micrococci* each one was 10(10.2%), *Salmonella* 7(7.1%), *Pseudomonas aeruginosa* and *Coagulase negative staphylococci* each one was 6(6.1%), *Proteus* 5(5.1%), *Staphylococcus aureus* and *Shigella* each one was 2 (2%) and *Streptococci* 1(1%), also for non diabetic patient *E.coli* was the most common etiologic agent 10(58.8%) followed by *Enterobacter* and *Proteus* each one was 3 (17.6%) and *Streptococci* 1(5.9%). Also we studied the relationship between percentage of infection and age of patients. Amikacin, ciprofloxacin and norfloxacin expressed the most effective antibiotics on these isolates but all these isolates were resistant to ampicillin/sulbactam, erythromycin, amoxicillin flomocin clavulanic acid and piperacillin except *Salmonella* was sensitive to amoxicillin flomocin clavulanic acid and *Enterobacter* was sensitive to piperacillin, the combination between ciprofloxacin and cefotaxim sodium is the most one which showed synergistic against bacterial isolates followed by ciprofloxacin and amikacin and amikacin and nitrofurantion, *Pseudomonas aeruginosa* was resistant to all antibiotic which used but showed synergistic against the combination between ciprofloxacin and amikacin, ciprofloxacin and norfloxacin, norfloxacin and amikacin and amikacin and nitrofurantion, also, the cell of *Pseudomonas aeruginosa* appear normal under electron microscope when not treated with norfloxacin but when treated with norfloxacin the cell become longer.

## الملخص العربي

### مقارنة البكتريا المسؤولة عن إصابات الجهاز البولي التناسلي للمضادات البكتيرية في النساء المصابات بمرض السكر

فتحى عواد منصور\* محمد فاروق غالى\*\* زينب على القناوى\*\*

كلية العلوم - قسم النبات - جامعة الزقازيق\*

كلية العلوم - قسم النبات - جامعة المنصورة\*\*

تعد إصابات الجهاز البولي التناسلي من أكثر الإصابات الباثولوجية شيوعاً والمصحوبة بزيادة المقاومة للمضادات البكتيرية، وقد أجريت هذه الدراسة لعزل البكتيريا من عينات بول تم تجميعها من نساء مصابات بمرض السكر وأخريات غير مصابات وتعريفها وتحديد مدى حساسيتها للمضادات البكتيرية، تم أيضاً دراسة التوافق والتضاد الناتج من الجمع بين المضادات البكتيرية ضد المعزولات البكتيرية. خلال هذه الدراسة تم تجميع ٢١١ عينة بول حيث وجد من بينهم ١١٥ حالة تعاني من وجود بكتيريا في البول (٩٨ مصابات بمرض السكر و١٧ غير مصابات)، بالنسبة لمرضى السكر كانت الأشريكية القولونية هي أكثر الأسباب شيوعاً ٢٧ (٦, ٢٧٪) ثم السراتيا ١٢ (٢, ١٢٪) ثم الستروبيكتنر والأنتيروبيكتنر والميكروكوكي كلاً منهم ١٠ (٢, ١٠٪) ثم السلامونيلا ٧ (١, ٧٪) ثم السودومونس أيروجينوزا والمكور العنقودي السالب لاختبار الكواجيليز كلاً منها يمثل ٦ (١, ٦٪) والبروتيس ٥ (١, ٥٪) والمكور العنقودي أوريس والشيجيلا كلاً منها كان ٢ (٢, ٢٪) والمكور السبحي ١ (١, ١٪). وأيضاً بالنسبة لغير المصابات بمرض السكر كانت الأشريكية القولونية هي أكثر الأسباب شيوعاً ١٠ (٨, ٥٨٪) ثم الأنتيروبيكتنر والبروتيس كلاً منهما ٣ (٦, ١٧٪) والمكور السبحي ١ (١, ٥٩٪). وقد تم دراسة العلاقة بين نسبة الإصابة وعمر المرضى، من خلال الدراسة وجد أن الأميكاسين والسيبروفلوكساسين والنورفلوكساسين كانت هي الأكثر فاعلية ضد هذه المعزولات وكانت جميع المعزولات مقاومة لمضادات الأميسلين والأرسروميسن والأمكسيسلين فلوموسين حمض الكلافيولنك والبيبراسلين ماعدا السلامونيلا كانت حساسة للأمكسيسلين فلوموسين حمض الكلافيولنك والأنتيروبيكتنر كانت حساسة للبيبراسلين، وكان الجمع بين السيبروفلوكساسين مع السيفاتكسام صوديوم قد أظهر تأثيراً توافيقياً ضد المعزولات البكتيرية يليه الجمع بين السيبروفلوكساسين مع الأميكاسين والجمع بين الأميكاسين مع النيتروفليورنتيون، كانت السودومونس أيروجينوزا مقاومة لجميع المضادات البكتيرية المستخدمة لكنها أظهرت تأثيراً عند الجمع بين السيبروفلوكساسين مع النورفلوكساسين والنورفلوكساسين مع الأميكاسين والأميكاسين مع النيتروفليورنتيون. وقد ظهرت خلية السودومونس أيروجينوزا بشكل طبيعي تحت الميكروسكوب الإلكتروني عندما لم تعالج بالنيتروفليورنتيون لكن عند العلاج بالنيتروفليورنتيون فقد أصبحت الخلية أكثر إستطالة.

## INTRODUCTION

Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year. Women are especially prone to UTI, One woman is five develops a UTI during her lifetime.

During any given year, 11 percent of wom-

en report had a urinary tract infection, and more than half of all women have at least one such infection during their lifetime (Foxman et al 2000).

Urinary tract infection (UTI) is a bacterial infection that affects any part of the urinary tract. Normally, urine is sterile and it is usually free of bacteria, viruses, and fungi because it contains a variety of fluids, salts, and

waste products but the infection occurs when any organisms, usually bacteria from the digestive tract, cling to the opening of the urethra and begin to multiply, the most of these organisms is *Escherichia coli* (*E. coli*), which normally lives in the colon, in addition to *E. coli*, other organisms such as *Klebsiella* spp, *Proteus* spp, *Enterobacter* spp, *Citrobacter* spp, *Salmonella* other *Enterobacteriaceae*, *Staphylococcus* spp, *Streptococci*, *enterococci* and *Pseudomonas* spp may be involved. In most cases bacteria travel to the urethra and multiply causing urethra infection (urethritis) and if the bacteria move to the bladder and multiply, a bladder infection (cystitis) can occur. If the infection is not treated promptly, bacteria may then travel further up the ureters to multiply and reach to the kidneys causing kidney infection (pyelonephritis) which is much more serious because it leading to kidneys damaged if a UTI is not treated for months or years. The urinary system is structured in a way that helps ward off infection in which the ureters and bladder normally prevent urine from backing up toward the kidneys and the flow of urine from the bladder helps wash bacteria out of the body (Meyhoff et al 1981, Jepson et al 2000, Liza et al 2003, Bethesda 2005 & David et al 2008).

*Pseudo-monas* species which caused UTI are known to be associated with hospital infections (Hilf et al 1989 & Goetz and Yu 1997). Sexual intercourse is thought to facilitate migration of the organisms from the urethra into the bladder before initiation of infection (Buckely et al 1978 & Nicolle et al 1982).

Urinary tract infections (UTIs) are charac-

terized as being either upper or lower based primarily on the anatomic location of infection: the lower urinary tract encompasses the bladder and urethra, and the upper urinary tract encompasses the ureters and kidneys. The anatomy of the female urethra is of particular importance to the pathogenesis of UTIs as it is relatively short compared with the male urethra and also lies in close proximity to the warm, moist, perirectal regions, which is meeting with microorganisms. Because of the shorter urethra, bacteria can reach the bladder more easily in the female host (Betty et al 1998).

Urinary tract bacterial infection are common in women. Moreover, they tend to recur through out life especially with frequent sexual activity, pregnancy, stones disease or diabetes (Jeanne and F.Gary 2005).

Most infections in diabetic patients are located in the urinary tract and in diabetic women, these infections occur frequently, can have a complicated course, are more difficult to treat and often recur than non diabetic patient because of the multiple effects of the disease on the urinary tract and host immune system (Vejlsgaard 1966, I. M. Hoepelman 1994 & Patterson and Andriole 1997).

Several types of urinary tract infections occur more commonly in diabetic patients and these include increasing in clinical severity, asymptomatic bacteriuria, cystitis, emphysematous cystitis, pyelonephritis and emphysematous pyelonephritis and perinephric abscess, emphysematous infections refer to those complicated by gas formation due to

bacterial fermentation and this may occur in the bladder (cystitis) or in the renal pelvis or parenchyma (pyelonephritis) (Ankel et al 1990).

Urinary tract infections (UTI) are very often encountered in patients with diabetes mellitus. They may present themselves as asymptomatic bacteriuria, but may also lead to more serious infection. Asymptomatic bacteriuria is more prevalent in women, but not men, with diabetes mellitus compared to controls. The increased prevalence of UTIs in diabetic patients can be the result of differences in the host responses between diabetic and non diabetic patients, or a difference in the infecting bacterium itself, the bacteria causing UTIs in diabetic patients are the same as in complicated UTIs in non diabetic patients. *E. coli* is the most common causative microorganism, *Klebsiella*, *Enterobacter*, *Serratia* spp. and *Streptococcus faecalis* have been isolated (I. M. Hoepelman 1994).

A common source of infection is catheters, or tubes placed in the urethra and bladder. A person who cannot void or who is unconscious or critically ill often needs a catheter that stays in place for a long time. Some people, especially the elderly or those with nervous system disorders who lose bladder control, may need a catheter for life. Bacteria on the catheter can infect the bladder. People with diabetes have a higher risk of a UTI because of changes in the immune system. Any other disorder that suppresses the immune system raises the risk of a urinary infection. According to several studies, women who use a diaphragm are more likely to develop a UTI than women who use other forms of birth

control (Bethesda 2005).

Antimicrobials such as piperacillin should be considered empiric antibiotic for catheter-associated UTIs and these agents have activity against many nosocomially acquired Gram-negative rods, including *P. aeruginosa* (Moelering 1998).

Trimethoprim-sulphamethoxazole was recommended as initial therapy of UTI, but only in communities where prevalence of trimethoprim-sulphamethoxazole resistance is less than 20% (J.W. Warren et al 1999).

The antimicrobial agent with the highest levels of activity against Gram-negative bacilli was amikacin which was restricted to hospital use while ciprofloxacin and nitrofurantoin showed acceptable levels of activity. Nitrofurantoin was active against all strains of *S. aureus* but there is a reduction in the activity of amoxicillin with clavulanate and quinolones to *E. coli*. (Rosa et al 2001).

## **MATERIALS AND METHODS**

Two hundred and eleven diabetic and non diabetic cases were subject to this study and admitted public hospital and kidney center at Mansoura. Ages of cases were ranged from 20 to 70 years. This study was done over a period of one year.

Urine samples are most commonly collected by sampling the mid stream flow by the clean-catch technique (Bradbury 1988). Once collected, a specimen of urine must be transported to the laboratory without delay (J. A. Porter and J. Brodie 1969).

**Identification of microorganisms :-**

All urine samples were inoculated on blood agar for 24h at 37°C and bacterial identification was based on culture and biochemical characteristics. Bacteria were identified by standard biochemical tests such as lactose fermentation, methyl red, citrate, indole, oxidase, coagulase, urease and H<sub>2</sub>S production (Koneman et al 1997, Sonnenwirth 1980, Collee and Marr 1996, Barron et al 1994, Smith 1980, Cheesbrough 2000, Bowden 1990 and Wolfgang et al 1998).

**Susceptibility testing :-**

Susceptibility tests were done according to the Kirby-Bauer disc diffusion method (Bauer et al 1986). Antimicrobial agents tested were ciprofloxacin, norfloxacin, amikacin, nitrofurantion, cefotaxim sodium, ampicillin sulbactam, piperacillin, erythromycin, trimethoprim sulfamethoxazole and amoxicillin clavulanic acid.

The synergetic and antagonistic of the most active antibiotic (ciprofloxacin, norfloxacin, amikacin, nitrofurantion and cefotaxim sodium) were examined against isolated bacteria according to (Marie Tre-Hardy et al 2008).

**RESULTS**

We analysed 211 urine samples, of which 115 (98 from diabetic and 17 from non diabetic) have significant bacteriuria, for diabetic women *E.coli* was the predominant causative agent 27 (27.6%) followed by *Serratia* 12 (12.2%), *Citrobacter*, *Enterobacter* and *Micrococci* each one was 10 (10.2%), *Salmonella* 7 (7.1%), *Pseudomonas aeruginosa* and Coagulase negative staphylococci each one was 6

(6.1%), *Proteus* 5 (5.1%), *Staphylococcus aureus* and *Shigella* each one was 2 (2%) and *Streptococci* 1 (1%) also, for non diabetic women *E.coli* was the predominant causative agent 10 (58.8%) followed by *Enterobacter* and *Proteus* each one was 3 (17.6%) and *Streptococci* 1 (5.9%), The frequency of pathogenic bacterial isolates from positive collected samples of diabetic and non diabetic female were recorded in table (1) and (2).

For diabetic patients, the highest percentage rate obtained was 70.5% of positive samples found in female age from 41-50 years and for non diabetic patients, the highest percentage rate obtained was 71.4% of positive samples found in female age from 61-70 years as illustrated in fig (1).

We tested the antimicrobial agents against bacterial isolates and the result were showed in table (3) :-

Ampicillin sulbactam and erythromycin were resistant against all tested bacteria. Amikacin, ciprofloxacin and norfloxacin showed the high activity against bacterial isolates, amikacin was sensitive against *E.coli*, *Citrobacter*, *Enterobacter*, *Shigella*, *Proteus*, Coagulase negative staphylococci, *Micrococci* and *Streptococci*, norfloxacin was sensitive against *E.coli*, *Citrobacter*, *Salmonella*, *Serratia*, *Proteus*, Coagulase negative staphylococci, *Staphylococcus aureus* and *Streptococci*, ciprofloxacin was sensitive against *E.coli*, *Enterobacter*, *Serratia*, *Shigella*, Coagulase negative staphylococci, *Micrococci* and *Staphylococcus aureus*, amoxicillin clavulanic acid was sensitive against *Salmonella*. Piperacillin was sensitive against *Enterobacter*. Cefotaxim sodium was sensitive against

E.coli, Citrobacter, Salmonella and Streptococci. Nitrofurantion was sensitive against Citrobacter, Serratia, Proteus and Micrococci. Trimethoprim sulfamethoxazole was sensitive against Enterobacter, Serratia and Micrococci.

Synergetic and antagonism of the most active antibiotics (ciprofloxacin, norfloxacin, amikacin, nitrofurantion and cefotaxim sodium) were tested against bacterial isolates and the results were showed that:-

There is a synergitic between ciprofloxacin and norfloxacin against E.coli , Enterobacter, Pseudomonas aeruginosa, Micrococci and Streptococci, but there is antagonism between them against Serratia and Staphylococcus aureus .

There is a synergism between ciprofloxacin and amikacin against E.coli, Citrobacter, Enterobacter, Salmonella, Pseudomonas aeruginosa and Coagulase negative staphylococci but there is antagonism between them against Shigella, Micrococci and Streptococci.

There is a synergism between ciprofloxacin and nitrofurantion against Citrobacter, Enterobacter, Salmonella and Shigella, but there is antagonism between them against E.coli, Serratia, Micrococci, Staphylococcus aureus and Streptococci .

There is a synergism between ciprofloxacin and cefotaxim sodium against E.coli, Citrobacter, Enterobacter, Salmonella Serratia, Shigella and Staphylococcus aureus, but there is antagonism between them against Proteus and Streptococci .

There is a synergism between norfloxacin and amikacin against E.coli, Shigella, Pseudomonas aeruginosa and Streptococci, but there is antagonism between them against Citrobacter, Proteus, Coagulase negative staphylococci and Micrococci .

There is a synergism between norfloxacin and nitrofurantion against E.coli, Enterobacter , Salmonella and Shigella, but there is antagonism between them against Citrobacter, Serratia, Pseudomonas aeruginosa , Proteus and Coagulase negative staphylococci.

There is a synergism between norfloxacin and cefotaxim sodium against Citrobacter, Enterobacter and Proteus , but there is antagonism between them against Salmonella and Shigella .

There is a synergism between amikacin and nitrofurantion against E.coli, Enterobacter, Salmonella, Pseudomonas aeruginosa, Coagulase negative staphylococci and Micrococci , but there is antagonism between them against Proteus and Staphylococcus aureus .

There is a synergism between amikacin and Cefotaxim sodium against E.coli , Citrobacter, Enterobacter, Coagulase negative staphylococci and Streptococci , but there is antagonism between them against Serratia , Micrococci and Staphylococcus aureus .

There is a synergism between nitrofurantion and Cefotaxim sodium against E.coli , Enterobacter and Shigella , but there is antagonism between them against Citrobacter , Serratia , Proteus , Micrococci and Staphylococcus aureus .

## DISCUSSION

This study shows the distribution of bacteria isolated from patient with urinary tract infection and their susceptibility pattern to antibiotics .

*Escherichia coli* was responsible for about 65.1% of urinary tract infection in different parts of Britain where as other coliforms than *E. coli* were 23.4% , 4.6% *Proteus* and *Morganella* spp., 1.8% *Pseudomonas* spp., 2.4% enterococci, 0.7% group B streptococci, 1.5% coagulase-negative staphylococci and 0.5% *Staphylococcus aureus*. (S. P. Barrett et al 1999).

The frequency of *E.coli* in urine samples varies in different studies from 32% (K. okada et al 1994) to intermediate values 40% (F.A.orret and S.M.shurland 1998), to 86%( Gupta et al 1999 & J.c.Nunezsanchez et al 1999), to 65% (J.C.Nunezsanchez et al 1999 & S.P.Barrett et al 1999). A result in Spain was 47% fit with the previous result (Rosa et al 2001).

*E.coli* was the predominant causative agent 27 (27.6%) and 10(58.8%) for diabetic and non diabetic women respectively followed by *Serratia* 12(12.2%) , *Citrobacter* , *Enterobacter* and *Micrococci* each one was 10 (10.2%) , *Salmonella* 7(7.1%) , *Pseudomonas aeruginosa* and *Coagulase negative staphylococci* each one was 6(6.1%) , *Proteus* 5 (5.1%) , *Staphylococcus aureus* and *Shigella* each one was 2(2%) and *Streptococci* 1(1%) for diabetic women but for non diabetic women it was followed by *Enterobacter* and *Proteus* each one was 3(17.6%) and *Streptococci* 1(5.9%) .

In this study we found that the incidence of bacteriuria was higher among diabetic women ages 41 to 50 (70.5%) and this probability decrease by 3.8 % with age 31-40 (66.7%) and the less incidence was among age of 20-30 (20%) which agree with those demonstrated by Nicolle et al who found that both men and women with diabetes have an increased risk of acute pyelonephritis requiring hospital admission. In a recent study, diabetes was estimated to increase this probability 20 to 30 fold under the age of 44 and three to five fold over the age of 44 (Nicolle et al 1996).

But the incidence of bacteriuria was higher among non diabetic women ages 61-70 (71.4) and this probability decrease by 17.6 % with age 20-30 year (53.8%) and the less incidence was among age of 41-50 and 51-60 , both were 0% which disagree with those demonstrated by Betty et al., 1998 and Geo.f. Brooks et al who found that the incidence of bacteriuria among girls age 5 through 14 is 1% to 2% . This incidence increases to 5% in girls over age 10. The prevalence of bacteriuria in females increases gradually with time to as high as 10% to 20% in elderly women. In women between the ages of 20 and 40 whom have UTIs , as many as 50% may become re-infected with 1 year. The association of UTIs with sexual intercourse may also contribute to this increased incidence because sexual activity serves to increase the chances of bacterial contamination of the female urethra (Betty et al 1998).

Pipercillin is effective against more than 80% of *Pseudomonas aeruginosa* strains (Allan Ronald 1984 and Moellering 1998 ) which

disagree with our results which showed that Piperacillin is resistant against *Pseudomonas aeruginosa*.

*Proteus* spp , *Citrobacter* spp and *Pseudomonas aeruginosa* showed resistance to ciprofloxacin ( Hilf et al 1989 & Goetz and Yu 1997) which agree with our results which showed that *Proteus* , *Citrobacter* and *Pseudomonas aeruginosa* were resistant to ciprofloxacin and disagree with other results which showed that ciprofloxacin is the most active against *Pseudomonas* species (O'Donnell and Gelone 2000).

Nitrofurantoin showed an acceptable level of activity against *Proteus* spp and non fermenting Gram-negative bacilli (D.Wolday and W.Erge 1997) which agree with our results which showed that nitrofurantoin was sensitive against *Proteus*. Nitrofurantoin was active against all strains of *S.aureus* (Rosa et al 2001) which disagree with our results which showed that Nitrofurantoin was resistant against *Staphylococcus aureus* .

Nitrofurantoin has no activity against *Pseudomonas aeruginosa* (Judith et al 2002)

which agree with ours .

The *E. coli* showed high rates of resistance to amoxicillin, amoxicillin-clavulanate and ciprofloxacin (Kader et al 2000 ) which agree with our results which showed that amoxicillin-clavulanate is resistant against *E.coli* but disagree with our as ciprofloxacin was sensitive against *E.coli* . The *E.coli* isolates were susceptible to nitrofurantoin and ciprofloxacin but resistant to ampicillin and trimethoprim (Leonid and Vladimir 2006) which agree with ours except that nitrofurantoin was resistant .

The combination between ciprofloxacin and cefotaxim sodium show the higher synergetic activity against bacterial isolates followed by the combination between amikacin and nitrofurantoin and the combination between amikacin and ciprofloxacin .

*Pseudomonas aeruginosa* was resistant against all antibiotic tested so we examined it under electron microscope after and before treated with norfloxacin and the cell appear normal when not treated but when treated the cell become longer .



**Table (1) : The frequency of the bacterial isolates from positive collected samples of diabetic females.**

Bacterial isolates	Count	Frequency
<i>E.coli</i>	27	27.6%
<i>Citrobacter</i>	10	10.2%
<i>Enterobacter</i>	10	10.2%
<i>Salmonella</i>	7	7.1%
<i>Serratia</i>	12	12.2%
<i>Shigella</i>	2	2%
<i>Pseudomonas aeruginosa</i>	6	6.1%
<i>Proteus</i>	5	5.1%
<i>Co-agulase negative staphylococci</i>	6	6.1%
<i>Micrococci</i>	10	10.2%
<i>Staphylococcus aureus</i>	2	2%
<i>Streptococci</i>	1	1%
<b>Total</b>	<b>98</b>	<b>100%</b>

Chi-Square Value =70.5

P Value = 0.0001

$$\text{Frequency} = \frac{\text{Positive samples}}{\text{Total samples}} \times 100$$

**Table (2) : The frequency of the bacterial isolates from positive collected samples of non diabetic females :-**

Bacterial isolates	Count	Frequency
<i>E.coli</i>	10	58.8%
<i>Enterobacter</i>	3	17.6%
<i>Proteus</i>	3	17.6%
<i>Streptococci</i>	1	5.9%
<b>Total</b>	<b>17</b>	<b>100%</b>

Chi-Square Value = 14.7

P Value = 0.002

Table (3) : Inhibition zone (mm) of different pathogenic bacterial isolates against different tested antibiotic.

		<i>E.coli</i>	<i>Citrobacter</i>	<i>Enterobacter</i>	<i>Salmonella</i>	<i>Serratia</i>	<i>Shigella</i>	<i>Pseudomonas aeruginosa</i>	<i>Proteus</i>	<i>Coagulase negative staphylococci</i>	<i>Micrococci</i>	<i>Staphylococcus aureus</i>	<i>Streptococci</i>
<b>Ampicillin Sulbactam (20µg)</b>	<b>IZ</b>	7	0	10	0	0	0	8	0	7	7	8	0
	<b>S</b>	R	R	R	R	R	R	R	R	R	R	R	R
<b>Amikacin (30µg)</b>	<b>IZ</b>	16	18	17	10	9	18	11	19	18	17	7	16
	<b>S</b>	I	S	S	R	R	S	R	S	S	S	R	I
<b>Cefotaxim Sodium (30µg)</b>	<b>IZ</b>	17	17	0	19	7	0	0	0	7	0	0	23
	<b>S</b>	M S	M S	R	M S	R	R	R	R	R	R	R	S
<b>Ciprofloxacin (5µg)</b>	<b>IZ</b>	23	7	25	12	22	21	12	8	21	18	21	8
	<b>S</b>	S	R	S	R	S	S	R	R	S	M S	S	R
<b>Nitrofurantion (300µg)</b>	<b>IZ</b>	0	21	13	0	17	0	0	18	0	19	0	0
	<b>S</b>	R	S	R	R	S	R	R	S	R	S	R	R
<b>Piperacillin (100µg)</b>	<b>IZ</b>	0	0	30	9	0	15	0	0	12	16	0	0
	<b>S</b>	R	R	S	R	R	R	R	R	R	R	R	R
<b>Erythromycin (15µg)</b>	<b>IZ</b>	0	7	0	0	6	0	0	7	0	0	0	0
	<b>S</b>	R	R	R	R	R	R	R	R	R	R	R	R
<b>Norfloxacin (30µg)</b>	<b>IZ</b>	16	16	12	17	17	12	12	18	19	7	20	18
	<b>S</b>	I	I	R	S	S	R	R	S	S	R	S	S
<b>Trimethoprim Sulfa-methoxazole (25µg)</b>	<b>IZ</b>	0	0	16	10	14	9	0	0	0	23	0	0
	<b>S</b>	R	R	S	R	M S	R	R	R	R	S	R	R
<b>Amoxicillin/Clavulanic acid (30µg)</b>	<b>IZ</b>	8	0	0	26	0	0	0	0	8	9	0	9

IZ = Inhibition zone


R=Resistant

I=Intermediate

MS=Moderately susceptible

S= Susceptible

Fig (1) : Bacterial culture of urine samples collected from diabetic and non diabetic female patients of different ages .



## REFERENCES

- Allan, R. Ronald (1984)** : Current concept in the management of urinary tract infection in Adults. Medical clinics of North America , vol . 68.,No.2.
- Ankel, F.; Wolfson, A. B and Stapczynski, J. S. (1990)** : Emphysematous cystitis : A complication of urinary tract infection occurring predominantly in diabetic women . Ann Emerg. Med. 19:404-406 .
- Barron, E. J. O.; Peterson, L. R. and Finegold, S. M. (1994)** : Enterobacteriaceae In Barron, E.J.O ; Peterson, L. R. and Finegold, S. M (eds) : Bailey and Scott's Diagnostic Microbiology, 362-385, Inc , Missouri .
- Bauer, A. W.; Kirby, W. M.; Sherris, J. C. and Turk, M. (1986)** : Antibiotic susceptibility testing by standardized single disk method Am. J .of Cl. Pathology; 45:493-496.
- Bethesda, M. D. (2005)** : National Kidney and Urologic Diseases Information Clearing house. NIH. Publication, No. 06 : 2097.
- Betty, A. forbes; Daniel, F. sahm and Alice, S. weiss feld (1998)** : Diagnostic microbiology. Tenth Edition. Moshy publishing.
- Bowden , G. H. W. (1990)** : Microbiology of root surface caries in human. J. Dent. Res., 69: 1205-1210.
- Bradbury, S. M. (1988)** : Collection of urine specimens in general practice : to clean or not to clean ? JR Coll Gen Pract , 38 : 363-365 .
- Buckely, R. M.; McGuckin, M. and MacGregor, R. R. (1978)** : Urine bacterial counts after sexual inter course. NEngl JMed, 298:321-324.
- Cheesbrough, M. (2000)** : Microbiological test . In : Cheesbrough, M. (ed) . District laboratory practice in tropical countries , 1-226. Cambridge University Press , U.K.
- D.wolday and W. Erge (1997)** : Increased Incidence of resistance at Ti- kur Anbessa Hospital . Ethiop. Med. J, 35:127-135.
- David, S. Howes; Joseph, A. Salomone; FranciscoTalavera; Richard Sinert ; John , D . Halamka and Pamela, L. Dyne (2008)** : Urinary tract infection, Female. emedicine from Web MD.
- F. A. Orret and S. M. Shurland (1998):** The changing patients of antimicrobial susceptibility of urinary pathogens in trinidad . Singapore Med . J, 39:256-259.
- Foxman, B.; Barlow, R.; D. Arcy, H.; Gillespie, B. and Sobel, J. D. (2000)** : Urinary tract infection : selfreported incidence and associated costs. Ann. Epidemoil, 10: 509-515.
- Goetz, A. and Yu, V. L. (1997)** : Intensive care unit : the hottest zone . Curr Opin Infect Dis , 10 : 319-323 .
- Gupta, K.; Scholes, D. and Stamm, W. E. (1999)** : Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. J. Am. Med. Assoc , 281:736-738.

**Hilf, M.; Yu, V. L.; Sharp, J.; et al., (1989)** : Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: outcome correlations a prospective study of 200 patients. *Am J Med*, 87: 540-546 .

**I. M. Hoepelman (1994)** : International journal of Antimicrobial Agents Vol 4:113-116.

**J. A. Porter and J. Brodie (1969)** : Boric acid preservation of urine samples . *Br Med J*. 10, 2(5653) : 353-355 .

**J. C. Nunezsanchez; M. T. Catala Barcelo; I. Navarro obrer and J. V. Balaquer Martinez (1999)** : Tratamiento delas infecciones urinarias en pacientes con factores deriesgo. *Med. Clin* , 24:558-559.

**J. W. Warren; E. Ablutyn; J. R. Hebel; J. R. Johnson; A. J. Schaeffer and A. E. Stamm (1999)** : Guidelines for antimicrobial treatment of un complicated acute bacterial cystitis and acute pyelonephritis in women. *Clin. Infect .Dis*, 29:745-658 .

**Jeanne, S. Sheffield and F. Gary Cunningham (2005)** : Urinary tract infection in women. *Obstetrics and Gynecology*, 106 : 1085-1095 .

**Jepson, R.; Mihaljevic, L. and Craig, J. (2000)** : cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev* :CD001321.PMID14973968(<http://www.ncbi.nlm.nih.gov/entrez/query.fc-gi>).

**Judith, A. O'Donnell; Steven, P. Gelone and Elius Abrutyn (2002)** : Selecting drug

regimens for urinary tract infections : current recommendations. *Infect Med* 19(1) : 14-22 .

**K. Okada; Y. Usui; T. Abe; et al., (1994)** : Statistics studies on bacteria isolated from urinary tract infections . *Hinyokika kiyo*, 40 : 175-185.

**Kadder, A. A.; Nassimuzzaman, M. and Dass, S. M. (2000)** : Antimicrobial resistance pattern of microorganisms isolated from blood cultures in a Saudi Arabian hospital. *BMJME*, 7:6-7 .

**Koneman, E. W.; Allen, S. D.; Janda, W. A.; et al., (1997)** : Guidelines for the collection transport, processing, analysis and reporting of cultures from specific specimen sources. In : Koneman, E.W; Allen, S.D; Janda, W. A; Schreckenberger, P.C and Winn, JRWC (eds) color atlas and text book of diagnostic. *Microbiology*. 121-162 . Lipincott Raven, Washington .

**Leonid, S. Stratchounski and Vladimir, V. Rafalski (2006)** : Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation : two multicentre studies, UTIAP-1 and UTIAP-2 *International Journal of Antimicrobial Agents*, Volume 28, Supplement 1, Pages 4-9 .

**Liza Dileo Thomas; Scott Hplantz; Francisco Talavera; Michael Dwitting; Jonathan Adler and James ungar (2003)** : urinary tract infection. e *Medicine world Medical Library* from Web MD.

**Marie Tre-Hardy; Francis Vanderbist; Hamidou Traore and Michel Jean Devleeschouwer (2008)** : In vitro activity of antibiotic combinations against *Pseudomonas aeruginosa* biofilm and planktonic cultures. International Journal of Antimicrobial Agent, 31 : 329-336 .

**Meyhoff, H.; Nordling, J.; Gammelgaard , P. and Vejlsgaard, R. (1981)** : Dose antibacterial ointment applied to urethral meatus in women prevent recurrent cystitis ? . Scand J Urol Nephrol 15 (2) : 81-3.PMID 7036332 (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>).

**Moellering , R.C.J.R. (1998)** : vancomycin - resistant enterococcus. Clin infect Dis , 26 : 1196-1199.

**Nicolle, L. E.; Harding, G. K. M.; Preiksaitis, J. and Ronald, A. R. (1982)** : The association of urinary tract infection with sexual intercourse. J infect Dis , 146:574-583.

**Nicolle, L. E.; Friesen, D.; Harding, G. K.; et al., (1996)**: Hospitalization for acute pyelonephritis in Manitoba , Canada , during the period from 1989 to 1992 , impact of diabetes, pregnancy , andaboriginal origin . clin Infect Dis , 22 (6) : 1051-6.

**O Donnell, J. A. and Gelone, S. P. (2000)** : The FLuoroquinolones . infect Dis clin. North. Am, 14:489-513.

**Patterson, J. E. and Andriole, V. T.**

**(1997)** : Bacterial urinary tract Infections in diabetes . Infect Dis cin North Am , 11(3) 735-750.

**Rosa Daza; Jose Gutierrez and Gonzalo Piedrole (2001)** : Antibiotic susceptibility of bacterial strains isolated from patients with community - acquired urinary tract infections. International Journal of Antimicrobial Agents, 18(3) : 211-215.

**S. P. Barrett; M. A. Savage; M. P. Rebec; A. Guyot; N. Andrews and S. B. Shrimpton (1999)** : Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. Journal of Antimicrobial Chemotherapy, 44, 359-365.

**Smith, A. L. (1980)** : Laboratory identification in microbiology and pathology 12th ed. The C.V.Mosby Company st . Lovis , Toronto , London . P 68 .

**Sonnenwirth, A. C. (1980)** : Gradwohol's Clinical Laboratory Methods and Diagnosis Vol . 2; 8th ed. Sonnenwirth; AC and Jarett L. (eds) . The CV Mosby Co. London; Tornto.

**Vejlsgaard R. (1966)** : studies on urinary infection in diabetics. I. bacteriuria in patients with diabetes mellitus and in control subjects. Acta Med scand, 179 : 173-182.

**Wolfgang, K. J. D.; Hilda, P. W.; Bernard, A. D. and Catherine, M. (1998)** : Oral microbiology . In Zinsser Microbiol 20th edition .